← All trials
NCT06423872
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 19, 2023
- Primary completion
- Oct 20, 2023
- Completion date
- Dec 8, 2023
- First posted
- May 21, 2024
- Last posted
- May 21, 2024
- Enrollment
- 28
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Beijing QL Biopharmaceutical Co.,LtdLead sponsor
- Peking UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.